Nirsevimab is a long-acting anti-RSV for nirsevimab for the prevention of RSV lower.
Diclofenac epolamine topical system is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
RiVive is an opioid antagonist that reverses the effects of opioids, including respiratory depression, sedation, and hypotension.
The resubmitted NDA was in response to a Complete Response Letter issued by the FDA in December 2021.
If approved, the OTC nasal spray would deliver 4mg of naloxone per spray.
Findings showed that the booster dose elicited robust antibody responses comparable to, or exceeding levels associated with the efficacy data in the primary series of the vaccine.
The 2022 CDC Clinical Practice Guideline is intended to help clinicians weigh the benefits and risks of opioids and alternative pain treatments for outpatients.
In general, routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications and should be completed by the end of October.
The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy.
Basimglurant is a potent, cell-penetrant negative allosteric modulator of mGlu5 receptors that works by lowering the perception of pain threshold.
